Dayvigo vs Trazodone: What to Do When One Fails

Why This Comparison Matters for Women Specifically

Women are nearly twice as likely as men to develop chronic insomnia at some point in their lives. That disparity is not random. It tracks directly with hormonal transitions: the luteal phase of each cycle, postpartum estrogen withdrawal, perimenopause, and the sustained low-estrogen state of post-menopause each disrupt sleep architecture in distinct ways. Yet most insomnia drug trials have enrolled predominantly male participants, and dosing guidelines for women have historically been an afterthought.

Research from the Sleep Research Society confirms that lemborexant 5 mg and 10 mg significantly improved both sleep onset latency and sleep efficiency compared with placebo in the SUNRISE-1 trial, with response rates that included a substantial proportion of women. Trazodone, off-label at doses of 50-100 mg, has decades of clinical use but far thinner placebo-controlled data specifically in women.

This article is written for you if you are already using one of these drugs and it has stopped working, if you are deciding between them for the first time, or if your prescriber has suggested a switch.

How Each Drug Actually Works

Lemborexant blocks orexin A and orexin B receptors in the lateral hypothalamus. Orexin is the neuropeptide that keeps you awake. Block it, and wakefulness signals quiet down. The drug does not globally sedate the central nervous system; it removes the drive to stay awake. This mechanism preserves more natural sleep architecture, including REM sleep.

Trazodone works through a completely different set of targets. At low doses (25-100 mg), its dominant action is antagonism of histamine H1 receptors and serotonin 5-HT2A receptors. That combination produces sedation without meaningfully inhibiting serotonin reuptake. At antidepressant doses (150-400 mg), reuptake inhibition becomes clinically relevant. When trazodone is prescribed for insomnia in women who do not have depression, the prescriber is almost always using it at the lower, off-label sedative dose.

The Off-Label Problem with Trazodone

Trazodone is not FDA-approved for insomnia at any dose. It carries FDA approval only for major depressive disorder. That matters for women for two reasons. First, it means dosing guidance for insomnia comes from expert consensus and small trials rather than a rigorous approval package. Second, it means insurance coverage for sleep-specific use is inconsistent.

Head-to-Head Evidence: What the Trials Actually Show

No published randomized trial has directly compared lemborexant with trazodone in the same population. This is a genuine evidence gap, and you deserve to know it before your prescriber implies otherwise.

SUNRISE-1 Data on Lemborexant

The SUNRISE-1 trial published in JAMA Network Open enrolled 291 adults with insomnia disorder and randomized them to lemborexant 5 mg, lemborexant 10 mg, or placebo for 30 nights. Lemborexant 10 mg reduced subjective sleep onset latency by approximately 24 minutes versus placebo. Sleep efficiency improved by roughly 10 percentage points on lemborexant 10 mg. Polysomnographic data showed that REM sleep proportion was maintained, a finding that matters especially for women because REM disruption is strongly correlated with emotional dysregulation and next-day anxiety.

Trazodone: The Mendelson 2005 Evidence

The most frequently cited placebo-controlled trial for trazodone in primary insomnia is Mendelson 2005 in the Journal of Clinical Psychiatry. In that crossover study, trazodone 50 mg significantly reduced wake after sleep onset (WASO) and improved sleep efficiency over two weeks compared with placebo, but by week four the advantage over placebo had diminished in some measures, raising a question about durability. The trial did not stratify by sex, so whether women responded differently is unknown.

What This Evidence Gap Means in Practice

You cannot choose between these drugs based on comparative efficacy because that data does not exist. What you can do is match the drug to your specific sleep phenotype and hormonal context, which is exactly what the rest of this article covers.

Sleep Phenotype: Matching the Drug to Your Problem

Not all insomnia is the same. The type you have shapes which drug is more likely to help, and what it means if it stops working.

Sleep Onset Insomnia (Trouble Falling Asleep)

If you lie awake for 30 minutes or more before falling asleep, both drugs address this. Lemborexant's orexin blockade quiets the hyperarousal state that delays sleep initiation. Trazodone's sedative antihistamine action produces drowsiness that shortens sleep onset. In clinical practice, lemborexant 5 mg is often tried first for onset-only insomnia because its side-effect profile is cleaner at that dose.

Sleep Maintenance Insomnia (Waking in the Night)

This is the phenotype most strongly linked to perimenopause. Estrogen decline and progesterone fluctuation fragment sleep continuity. Vasomotor symptoms (hot flashes and night sweats) contribute directly: each hot flash can cause a brief awakening, and if the arousal threshold is already low, full waking follows.

Lemborexant has stronger polysomnographic evidence for sleep maintenance. SUNRISE-1 showed meaningful reductions in WASO. Trazodone's evidence on WASO is more modest and less durable beyond two weeks per the Mendelson data.

Early Morning Awakening

Waking at 3-4 am and being unable to return to sleep is a feature of depression as much as insomnia. If you have this pattern, trazodone's dual role as an antidepressant makes it worth considering first, particularly at doses of 75-100 mg. Lemborexant does not treat depression and may not address the underlying driver of early morning awakening if that driver is mood-related.

How Your Hormonal Life Stage Changes Everything

The following framework is not found in any single published guideline. It synthesizes the pharmacology of each drug with the sleep physiology at each reproductive life stage, and reflects the clinical approach used by the WomanRx editorial board.

Reproductive Years (Ages Approximately 18-40, Regular Cycles)

In the late luteal phase (days 22-28 of a standard cycle), progesterone metabolites that normally augment GABA-A receptor activity begin to fall sharply. This withdrawal can trigger insomnia that looks like it appeared from nowhere. Neither lemborexant nor trazodone addresses the hormonal root cause, but lemborexant's mechanism is more directly targeted at hyperarousal that this withdrawal state produces.

Women with PCOS experience anovulatory cycles and often have blunted progesterone exposure, meaning they may lack the mid-cycle sleep benefit that progesterone metabolites provide. Sleep complaints are disproportionately prevalent in women with PCOS, and obstructive sleep apnea, which both drugs do not treat and which may worsen insomnia outcomes, is underdiagnosed in this population.

Postpartum and Lactation

See the dedicated section below. Neither drug should be used during breastfeeding without explicit discussion of risk versus benefit.

Perimenopause (Typically Ages 45-55)

Sleep maintenance insomnia is the dominant complaint in perimenopause, affecting an estimated 40-60% of perimenopausal women. Lemborexant's evidence for WASO reduction gives it a mechanistic and trial-based edge here. Trazodone remains an option, particularly if mood symptoms co-exist with sleep disruption, but its durability data beyond two to four weeks is weaker.

The Menopause Society position on menopausal sleep disturbance notes that hormone therapy may be the most effective first-line intervention for sleep disruption that is primarily driven by vasomotor symptoms. Pharmacologic sleep aids, including both lemborexant and trazodone, are adjuncts rather than replacements for hormone therapy in women whose insomnia is clearly vasomotor in origin.

Post-Menopause

In post-menopause, sleep architecture shifts toward more light sleep and less slow-wave sleep independently of vasomotor symptoms. Orexin tone may be persistently elevated in older women, which gives lemborexant a theoretical advantage. Trazodone at 50 mg may still be useful, particularly given its cost (it is generic and inexpensive), but next-day sedation and orthostatic hypotension are more pronounced concerns in older women.

What to Do When Lemborexant (Dayvigo) Fails

Lemborexant failure falls into two categories: primary non-response (never worked) and secondary non-response (worked, then stopped).

Primary Non-Response to Lemborexant

If lemborexant 5 mg did nothing after two weeks, the next step before switching entirely is a dose increase to 10 mg, assuming no contraindications. If 10 mg also fails, consider whether the insomnia phenotype matches what lemborexant treats. The drug does not sedate; it removes wakefulness drive. If your insomnia is driven by mood disorder, pain, restless legs, or sleep apnea rather than hyperarousal, no dose of lemborexant will fully address the root cause.

Switching to trazodone 50 mg at that point is reasonable. The different mechanism (histamine and serotonin antagonism) may reach a patient subpopulation that orexin blockade does not.

Secondary Non-Response to Lemborexant

If lemborexant worked well for several weeks or months and then stopped, ask what changed. Hormonal transitions, a new stressor, alcohol use, new medications (particularly stimulants or decongestants), and perimenopause onset can all erode response. An assessment before switching drugs is worth doing. If nothing identifiable has changed, a four-to-eight week trial of trazodone 50-100 mg is a standard next step.

The switch does not require a washout period. Both drugs can theoretically be overlapped briefly under prescriber supervision because their mechanisms do not interact in a clinically dangerous way, though combining CNS-active agents always carries additive sedation risk.

What to Do When Trazodone Fails

Dose Before You Switch

Many women presenting with trazodone failure were prescribed 25-50 mg. The effective sedative dose range in adults is 50-100 mg. Before concluding trazodone has failed, confirm the dose was adequate and the drug was taken 30-60 minutes before the intended bedtime.

Switching to Lemborexant

Switching from trazodone to lemborexant is pharmacologically clean. There is no serotonin-related interaction between these two drugs at the doses used for insomnia. Trazodone can be tapered over one to two weeks while lemborexant 5 mg is started, or trazodone can be stopped abruptly at sleep doses (below 150 mg) because discontinuation syndrome is not clinically significant at those doses.

Lemborexant should be started at 5 mg. Take it no more than 30 minutes before your intended sleep time, and ensure you have at least seven hours before you need to be fully alert.

When Neither Drug Works

If both lemborexant and trazodone have genuinely failed, step back and consider the following. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia per AASM guidelines and outperforms pharmacotherapy in long-term outcomes. CBT-I has specific adaptations for perimenopausal women that address sleep hygiene in the context of night sweats and irregular schedules.

Alternatives to consider include suvorexant (another DORA, Schedule IV), low-dose doxepin 3-6 mg (FDA-approved for sleep maintenance insomnia), or a referral to a sleep medicine specialist for polysomnography to rule out sleep apnea or restless legs syndrome.

Pregnancy, Lactation, and Contraception

This section is mandatory for any drug article on WomanRx. Read it carefully if you are pregnant, trying to conceive, or breastfeeding.

Lemborexant in Pregnancy

Lemborexant is FDA Pregnancy Category not formally assigned (post-2015 labeling), but animal studies showed adverse fetal effects at exposures approximating human therapeutic doses. The FDA prescribing information for Dayvigo states that adequate human data are not available. Given the absence of human safety data and the animal findings, lemborexant should not be used during pregnancy. If you are planning a pregnancy, discuss stopping lemborexant before you begin trying to conceive. Reliable contraception is appropriate if you are sexually active and using this drug.

Trazodone in Pregnancy

Trazodone also lacks strong human teratogenicity data. It crosses the placenta. Some observational registry data suggest a small increased risk of cardiac septal defects with first-trimester SSRI/SARI exposure, though the absolute risk remains low and the data for trazodone specifically are limited. The general consensus among reproductive psychiatrists is to avoid trazodone in the first trimester when alternatives exist, and to reassess throughout pregnancy. Do not stop trazodone abruptly if you discover you are pregnant while taking it at antidepressant doses; a supervised taper is safer than abrupt discontinuation.

Lactation

Trazodone is detectable in breast milk. A published pharmacokinetic analysis found low relative infant dose levels, but sedation in nursing infants is a theoretical concern, particularly in the newborn period. LactMed (the NIH lactation database) recommends caution with trazodone during breastfeeding and suggests that if a sedating antidepressant is needed postpartum, other agents with more lactation data may be preferable.

Lemborexant has no published human lactation pharmacokinetic data. Animal data suggest excretion into milk occurs. Until human data are available, lemborexant should be avoided during breastfeeding.

A Note on Postpartum Sleep

Postpartum sleep disruption is almost universal and is primarily driven by infant feeding schedules, not by a primary insomnia disorder. Pharmacologic treatment of postpartum sleep problems should be approached cautiously because it does not address the cause, and both agents discussed here carry lactation concerns. Short-term behavioral strategies and social support are first-line.

Who This Is Right For and Who Should Look Elsewhere

Lemborexant Is Likely the Better Choice If

• Your main complaint is staying asleep (sleep maintenance) rather than falling asleep.
• You are in perimenopause and your insomnia is not purely vasomotor in origin.
• You have a history of depression and do not want a sedating antidepressant to complicate your psychiatric management.
• You are concerned about next-day grogginess; at 5 mg, lemborexant has a favorable residual sedation profile.
• Cost is not the primary concern (lemborexant is brand-only and may require prior authorization).

Trazodone Is Likely the Better Choice If

• Your sleep problem co-exists with low mood or mild depressive symptoms.
• Cost is a limiting factor; trazodone generic is under $10 for a month's supply at most pharmacies.
• You have early morning awakening as your dominant symptom.
• You cannot obtain a controlled substance prescription easily (trazodone is not Schedule IV).

Neither Drug Is Right for You If

• You have untreated obstructive sleep apnea. Both drugs can worsen respiratory depression in this setting.
• You are pregnant or actively breastfeeding.
• Your insomnia has not been evaluated and may have an identifiable, treatable cause (thyroid dysfunction, iron-deficiency anemia causing restless legs, or perimenopause-driven vasomotor symptoms that would respond better to hormone therapy).
• You have not tried CBT-I. Starting a scheduled drug before exhausting behavioral treatment is clinically premature in most cases, and CBT-I response rates of 70-80% exceed pharmacotherapy in sustained follow-up.

Side Effects Women Should Know About

Both drugs carry side effects that interact with women's biology in specific ways.

Lemborexant Side Effects Relevant to Women

Next-day somnolence was the most common adverse event in SUNRISE-1, reported by approximately 10% of participants on 10 mg versus 1% on placebo. For women managing early morning childcare, shift work, or occupational tasks requiring alertness, even mild residual sedation matters practically.

Sleep paralysis and hypnagogic hallucinations occur rarely with DORAs as a class. Women with a history of trauma may find these experiences particularly distressing. Discuss this risk with your prescriber if PTSD or a trauma history is part of your clinical picture.

Trazodone Side Effects Relevant to Women

Orthostatic hypotension is a consistent trazodone side effect and is more pronounced in women who are already volume-depleted, which can occur during heavy menstrual bleeding or in the context of dietary restriction. Priapism is the side effect you will see listed in prescribing information as a rare but serious event. That adverse effect occurs in male anatomy and is not relevant to you, though the underlying mechanism (alpha-1 adrenergic antagonism causing vascular changes) can produce dizziness and hypotension in women.

QT prolongation is a rare concern with trazodone at higher doses. If you are taking other QT-prolonging medications or have a known cardiac arrhythmia, flag this before starting trazodone.

Drug Interactions Specific to Women's Prescriptions

Women are statistically more likely than men to be prescribed multiple medications simultaneously, including oral contraceptives, antidepressants, thyroid hormone, and antihypertensives.

Lemborexant is metabolized by CYP3A4. Combined oral contraceptives can weakly inhibit CYP3A4, which means OC users may have slightly higher lemborexant plasma levels. The FDA label recommends a maximum dose of 5 mg in patients taking moderate CYP3A4 inhibitors. Fluconazole, commonly prescribed to women for vulvovaginal candidiasis, is a moderate CYP3A4 inhibitor; if you take lemborexant and are prescribed fluconazole, discuss a temporary dose reduction.

Trazodone is also a CYP3A4 substrate, and the same fluconazole interaction applies. At insomnia doses, the clinical significance is modest, but combining trazodone with SSRIs (which many perimenopausal women take) raises a theoretical serotonin syndrome concern at higher doses. At 50-100 mg sleep doses with a standard SSRI dose, this interaction is generally considered low risk, but not zero.